Sling Therapeutics to Announce Topline Results from Phase 2b/3 LIDS Clinical Trial of Oral Small Molecule Linsitinib in Patients with Thyroid Eye Disease at the 43rd Annual J.P. Morgan Healthcare Conference

Sling Therapeutics to Announce Topline Results from Phase 2b/3 LIDS Clinical Trial of Oral Small Molecule Linsitinib in Patients with Thyroid Eye Disease at the 43rd Annual J.P. Morgan Healthcare Conference

ANN ARBOR, Mich., Jan. 13, 2025 /PRNewswire/ — Sling Therapeutics, Inc., a late-stage biopharmaceutical company focused…

Continue Reading
Skye Nixes Eye Disease Drug After Phase II Failure, Focuses on Metabolic Program

Skye Nixes Eye Disease Drug After Phase II Failure, Focuses on Metabolic Program

Pictured: Healthcare worker conducting an eye exam on a female patient/iStock, peakSTOCK Skye Bioscience announced Monday it…

Continue Reading